OM1, Inc.
OM1, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at OM1, Inc..
OM1, Inc. is a company.
Key people at OM1, Inc..
Key people at OM1, Inc..
OM1, Inc. is a Boston-based healthcare technology company founded in 2015 that specializes in real-world evidence (RWE) generation, personalized medicine, and outcomes research using AI-powered platforms and deep longitudinal patient data covering over 300 million lives[1][2][5]. It builds the OM1 Real-World Data Cloud, including tools like the OM1 Engine for data processing, OM1 AI for advanced analytics and personalization, and automated data networks, serving pharmaceutical companies, providers, payers, and researchers to accelerate drug approvals, predict patient outcomes, and support value-based care in chronic diseases like neurology and rheumatoid arthritis[2][3][5]. With $171 million in funding, $42 million in revenue, and 188 employees, OM1 demonstrates strong growth, evidenced by recent awards such as the 2024 Frost & Sullivan New Product Innovation Award and recognition in the 2025 Frost Radar for Life Sciences RWE[1][5].
OM1 was founded in 2015 by Dr. Rich Gliklich, a Harvard Medical School professor, surgeon at Massachusetts Eye and Ear Infirmary, and outcomes research expert who previously built an outcomes-focused company from his Harvard lab[3]. Based initially in Cambridge, Massachusetts (now Boston), the company emerged from Gliklich's expertise in healthcare informatics to address gaps in measuring and predicting patient outcomes using real-world data[1][3]. Early traction included building a "cognitive cloud platform" with robust datasets and a paid research initiative to partner with physician practices, offering MIPS reporting under MACRA for reimbursement while gathering precision analytics[3]. This evolved into specialized focus on chronic diseases, AI integration, and RWE from bench-to-practice[2].
OM1 stands out in the RWE and healthcare AI space through:
OM1 rides the explosive growth in real-world evidence (RWE) and AI-driven personalized medicine, fueled by regulatory shifts like FDA emphasis on RWE for approvals and post-market surveillance amid rising chronic disease prevalence[2][5]. Timing is ideal as healthcare digitizes post-pandemic, with demands for precise, predictive analytics to cut trial costs, identify responders, and enable value-based care—market forces like AI adoption in life sciences (projected multi-billion growth) favor OM1's 300M+ patient cloud[1][2]. It influences the ecosystem by setting benchmarks in RWE quality (e.g., high-rated RA datasets), accelerating neurology innovation, and bridging industry-provider gaps through partnerships, positioning it as a top contender per Frost & Sullivan[5].
OM1 is poised for expansion with recent leadership additions like Chief Product Officer Hunter Lane and dataset growth, targeting deeper AI-enabled evidence for emerging therapies in neurology and beyond[5]. Trends like AI regulatory acceptance, digital phenotyping, and payer demands for outcomes data will propel it, potentially scaling to new diseases or global markets via ISPOR Europe engagements[5]. Its influence may evolve from data provider to ecosystem orchestrator, enhancing personalized impact as RWE becomes standard—reinforcing its mission to transform healthcare measurement from reactive to pre-emptive[4].
